MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
1.605
-0.005
-0.31%
After Hours: 1.590 -0.015 -0.93% 19:30 09/25 EDT
OPEN
1.660
PREV CLOSE
1.610
HIGH
1.750
LOW
1.580
VOLUME
458.95K
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.8200
MARKET CAP
13.69M
P/E (TTM)
-0.5258
1D
5D
1M
3M
1Y
5Y
1D
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
Barchart · 1d ago
BioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
TipRanks · 5d ago
Weekly Report: what happened at BIVI last week (0914-0918)?
Weekly Report · 6d ago
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
Barchart · 09/19 10:45
Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
Barchart · 09/18 08:00
What's Going On With BioVie Stock on Tuesday?
Benzinga · 09/15 16:21
BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down
NASDAQ · 09/15 12:24
BioVie announces topline results from ADDRESS-LC trial
TipRanks · 09/15 11:40
More
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.